注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Sumitomo Dainippon Pharma Co., Ltd., 是一家制药公司。日本部门生产和销售处方药物和一般用途药物。北美部门生产、开发、购买和销售处方药品。中国部门通过其子公司生产和销售处方药品。其他海外部门在欧洲涉及其产品的发展。该公司还从事生产、采购、销售和供应食品材料及添加剂、化工产品、兽药、诊断产品和动物临床病理检查服务、提取物的制造以及药品的贮存、运送和临床检查。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Hiroshi Nomura | 65 | 2012 | CEO, President & Representative Director |
Mayumi Mochizuki | - | 2021 | Outside Audit & Supervisory Board Member |
Daishiro Michimori | - | 2022 | Outside Audit & Supervisory Board Member |
Takashi Kutsunai | 65 | 2014 | Full-Time Audit & Supervisory Board Member |
Hiroyuki Baba | 64 | 2014 | Mngg Exec. Officer of Global Data Design, Lgl Affairs. IP, IT Mgt, & Frontier Bus. Off. & Director |
Yoshiharu Ikeda | 65 | 2020 | Managing Executive Officer of Drug Research Division, Head of Japan Business Unit & Director |
Nobuhiro Endo | 70 | 2019 | Independent Outside Director |
Toru Kimura | 63 | 2016 | Sr. Mngg Exec. Off. of Glo. Crprate Stgy, F&A, Regen & Cell Med. Off., Kobe Ctr, Mfg. Plt and Dir. |
Shigeyuki Nishinaka | 59 | 2014 | Managing Executive Officer of Business Development & Management and Director |
Minoru Usui | 68 | 2021 | Independent Outside Director |
Koji Fujimoto | 60 | 2022 | Independent Outside Director |
Yoshio Iteya | 67 | 2018 | Outside Audit & Supervisory Board Member |
Hisayoshi Kashima | - | 2014 | Full-Time Audit & Supervisory Board Member |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核